Researchers Identify Intracellular Pathway Of Alfacell's ONCONASE(R)

Alfacell
Corporation (Nasdaq: ACEL) today announced that European researchers have
identified the pathway that ONCONASE (ranpirnase) follows to enter cells.


Published in the Journal of Cell Science (2007; 120: 1405-1411), a
paper based on studies conducted at the University of Girona in Spain and
the University of Montpellier II in France shows that ONCONASE enters cells
using AP-2/clathrin-mediated endocytosis, enabling its subsequent delivery
to the cytosol. The published data indicate that unlike other RNases, the
ONCONASE endocytosis pathway is not targeted to lysosomes.



"ONCONASE has a very specific property in that it is selectively toxic
to malignant cells," said Kuslima Shogen, Alfacell's chairman and chief
executive officer. "The Journal of Cell Science paper is another reflection
of the strong interest that the scientific and medical communities have in
understanding ONCONASE's performance. Ongoing independent research like
this at leading institutions is providing us with further data that is
useful in our efforts to expand the potential therapeutic opportunities for
our technology platform."



About ONCONASE(R)



ONCONASE is a first-in-class therapeutic product candidate based on
Alfacell's proprietary ribonuclease (RNase) technology. A natural protein
isolated from the leopard frog, ONCONASE has been shown in the laboratory
and clinic to target cancer cells while sparing normal cells. ONCONASE
triggers apoptosis, the natural death of cells, via multiple molecular
mechanisms of action.



About Alfacell Corporation



Alfacell Corporation is the first company to advance a
biopharmaceutical product candidate that works in a manner similar to RNA
interference (RNAi) through late-stage clinical trials. The product
candidate, ONCONASE, is an RNase that overcomes the challenges of targeting
RNA for therapeutic purposes while enabling the development of a new class
of targeted therapies for cancer and other life-threatening diseases. In
addition to an ongoing Phase IIIb study in malignant mesothelioma, Alfacell
is conducting a Phase I/II trial of ONCONASE in non-small cell lung cancer
(NSCLC) and other solid tumors. For more information, visit
alfacell.




Safe Harbor



This press release includes statements that may constitute "forward-
looking" statements, usually containing the words "believe," "estimate,"
"project," "expect" or similar expressions. Forward-looking statements
involve risks and uncertainties that could cause actual results to differ
materially from the forward-looking statements. Factors that would cause or
contribute to such differences include, but are not limited to,
uncertainties involved in transitioning from concept to product,
uncertainties involving the ability of the company to finance research and
development activities, potential challenges to or violations of patents,
uncertainties regarding the outcome of clinical trials, the company's
ability to secure necessary approvals from regulatory agencies, dependence
upon third-party vendors, and other risks discussed in the company's
periodic filings with the Securities and Exchange Commission. By making
these forward-looking statements, the company undertakes no obligation to
update these statements for revisions or changes after the date of this
release.


Alfacell Corporation

alfacell